Novartis Japanese Unit Moves Drug For Treating Several Cancers
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma KK of Japan says it plans to seek approval for a pancreatic-cancer drug as early as next year, after it completes current Phase III trials. The Japanese arm is developing the drug through several stages for various treatments, leading with an application already filed for using it to treat renal cell carcinoma. Novartis Pharma also expects to begin Phase III trials for RAD001 within a year for treating stomach cancer. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.